Shopping Cart

Your shopping cart is currently empty

Tesaglitazar

Name: Tesaglitazar
Brand: TargetMol
SKU: T17044
Price: 38 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T17044Cas No. 251565-85-2

Tesaglitazar is a potent and selective peroxide PPARα / γ receptor dual agonist with a more potent affinity for PPARγ than PPARα, The EC50 values for rat PPARα and human PPARα were 13.4 μM and 3.6 μM, respectively, and 0.2 μM for rat PPARγ and human PPARγ. Tesaglitazar induced DNA synthesis and fibrosarcoma formation in rat subcutaneous mesenchymal cells.

Tesaglitazar

Copy Product Info

😃Good

Purity: 99.95%

Catalog No. T17044Cas No. 251565-85-2

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$38	In Stock	-
5 mg	$89	In Stock	-
10 mg	$139	In Stock	-
25 mg	$268	In Stock	-
50 mg	$450	In Stock	-
100 mg	$703	4-6 weeks	4-6 weeks
200 mg	$973	4-6 weeks	4-6 weeks
1 mL x 10 mM (in DMSO)	$98	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products.If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.95%

ee:100%

Appearance:Solid

Color:White

Resource Download

COA HNMR CSFC LCMS ORP

Product Introduction

Bioactivity

Description	Tesaglitazar is a potent and selective peroxide PPARα / γ receptor dual agonist with a more potent affinity for PPARγ than PPARα, The EC50 values for rat PPARα and human PPARα were 13.4 μM and 3.6 μM, respectively, and 0.2 μM for rat PPARγ and human PPARγ. Tesaglitazar induced DNA synthesis and fibrosarcoma formation in rat subcutaneous mesenchymal cells.
Targets&IC50	PPARα(human):3.6 μM(EC50), PPARα (rat):13.4 μM(EC50), PPARγ:0.2 μM(EC50)
In vivo	The aim of the present study was to determine whether tesaglitazar attenuates NAFLD and atherosclerosis development in diabetic low-density lipoprotein receptor-deficient (LDLr(-/-)) mice. Tesaglitazar therapeutic group (n=15, 20 μg/kg/day oral treatment for 6 weeks). Tesaglitazar decreased serum glucose and lipid levels compared with the diabetic mice and significantly reduced atherosclerotic lesions, lipid accumulation in the liver, macrophage infiltration, and decreased total hepatic cholesterol and triglyceride content compared to the diabetic mice. In addition, tesaglitazar reduced inflammatory markers at both the serum and mRNA levels. Tesaglitazar may be effective in preventing NAFLD and atherosclerosis in a pre-existing diabetic condition by regulating glucose and lipid metabolism, and the inflammatory response.[1]

Chemical Properties

Molecular Weight	408.47
Formula	C₂₀H₂₄O₇S
Cas No.	251565-85-2
Smiles	CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O
Relative Density.	1.278 g/cm3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 260 mg/mL (636.52 mM), Sonication and heating to 60℃ are recommended.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.4482 mL	12.2408 mL	24.4816 mL	122.4080 mL
5 mM	0.4896 mL	2.4482 mL	4.8963 mL	24.4816 mL
10 mM	0.2448 mL	1.2241 mL	2.4482 mL	12.2408 mL
20 mM	0.1224 mL	0.6120 mL	1.2241 mL	6.1204 mL
50 mM	0.0490 mL	0.2448 mL	0.4896 mL	2.4482 mL
100 mM	0.0245 mL	0.1224 mL	0.2448 mL	1.2241 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc